Skip to main content

Table 3 Clinical and laboratory characteristics of the group of patients (12 patients) where LEF-1 was remeasured at day 28

From: Lymphoid enhancer-binding factor 1 (LEF-1): a favorable prognostic factor in adult acute myeloid leukemia in Egyptian patients

Case (N)Age (years)SexCytogeneticHb (g/dl)TLC × 109/LPlt × 109/LPB blast %BM blast %LEF-1 (log10)Follow-up LEF-1 (log10)FateResponse (D 28)
132Ft(15;17)9.15.8114127013.933.21AliveHR
230Ft(8,21)10.99.6111308015.512.11AliveHR
350Ft(8,21)9.112.380168811.511.74AliveHR
432Mt(8,21)8.61080245611.391.36AliveHR
547MNormal9690158012.1312.28DiedIR
628FNormal13.13.77788513.0713.31DiedIR
736MNormal8.6128899910.119.95DiedIR
853Ft(15,17)94156309515.392.51AliveHR
930Mt(15,17)10480353013.521.82AliveHR
1037Mt(15,17)11590406011.531.93AliveHR
1164M11q236.483.72890910.70.5DiedIR
1268M11q236.670.81640671.781.62DiedIR
  1. N = number, F female, M male, Hb hemoglobin, TLC total leucocytic count, PB peripheral blood, BM bone marrow, LEF-1, lymphoid enhancer binding factor 1, HR hematological remission, IR incomplete remission